Clinical Trials
2 trialsNCT05567185 2026-06-05
TAR-210
Janssen Pharmaceutical K.K.
Phase 1 Active not recruiting
NCT03547037 2025-04-28
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
Janssen Pharmaceutical K.K.
Phase 1 Completed